AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for TATA box-binding protein-associated factor RNA polymerase I subunit B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q53T94

UPID:

TAF1B_HUMAN

Alternative names:

RNA polymerase I-specific TBP-associated factor 63 kDa; TATA box-binding protein-associated factor 1B; Transcription initiation factor SL1/TIF-IB subunit B

Alternative UPACC:

Q53T94; B4DI42; F8WD72; Q15574; Q8WVC3

Background:

The TATA box-binding protein-associated factor RNA polymerase I subunit B, also known as RNA polymerase I-specific TBP-associated factor 63 kDa, TATA box-binding protein-associated factor 1B, and Transcription initiation factor SL1/TIF-IB subunit B, is pivotal in transcription initiation. It is a component of the RNA polymerase I core factor complex, acting similarly to GTF2B/TFIIB, and is crucial for pre-initiation complex assembly and post-polymerase recruitment in Pol I transcription.

Therapeutic significance:

Understanding the role of TATA box-binding protein-associated factor RNA polymerase I subunit B could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.